Shopping Cart
- Remove All
Your shopping cart is currently empty
GK563, a selective Ca 2+-independent phospholipase A2 (GVIA iPLA2) inhibitor, exhibits a potent IC50 value of 1 nM and demonstrates 22,000-fold greater activity against GVIA iPLA2 compared to GIVA cPLA2. Its efficacy in reducing β-cell apoptosis triggered by proinflammatory cytokines suggests potential therapeutic benefits in combating autoimmune disorders, including type 1 diabetes.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $337 | 35 days | |
| 5 mg | $1,430 | 35 days | |
| 10 mg | $2,580 | 35 days |
| Description | GK563, a selective Ca 2+-independent phospholipase A2 (GVIA iPLA2) inhibitor, exhibits a potent IC50 value of 1 nM and demonstrates 22,000-fold greater activity against GVIA iPLA2 compared to GIVA cPLA2. Its efficacy in reducing β-cell apoptosis triggered by proinflammatory cytokines suggests potential therapeutic benefits in combating autoimmune disorders, including type 1 diabetes. |
| Molecular Weight | 246.34 |
| Formula | C16H22O2 |
| Cas No. | 2351820-19-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.